Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study - Salles, G; Duell, J; González Barca, E (Lancet Oncol, 2020)